Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
16.38
+0.39 (2.44%)
Feb 21, 2025, 4:00 PM EST - Market closed
Syndax Pharmaceuticals Revenue
Syndax Pharmaceuticals had revenue of $12.50M in the quarter ending September 30, 2024. This brings the company's revenue in the last twelve months to $16.00M.
Revenue (ttm)
$16.00M
Revenue Growth
n/a
P/S Ratio
84.07
Revenue / Employee
$86,957
Employees
184
Market Cap
1.40B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
SNDX News
- 11 days ago - Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law Firm - GlobeNewsWire
- 18 days ago - Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PRNewsWire
- 23 days ago - Syndax Announces Participation in February Investor Conferences - PRNewsWire
- 5 weeks ago - Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes - PRNewsWire
- 5 weeks ago - Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 6 weeks ago - Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 2 months ago - Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial - PRNewsWire
- 2 months ago - Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting - PRNewsWire